Reata Pharmaceuticals, Inc. (RETA), a Healthcare Biotechnology organization, saw its stock trade 219.68 shares, decrease against to its 10-day trading volume of 458.5k.
Reata Pharmaceuticals, Inc. (RETA) stock traded at $226.89, up 8.10 cents or +3.70% on the day.
Total Revenue for Reata Pharmaceuticals, Inc. (RETA) is $31.34M, Gross Profit is $-44.94M and the EBITDA is $-124.93M.
Reata Pharmaceuticals, Inc. (RETA) Technical Details:
The average 10-day trading volume of Reata Pharmaceuticals, Inc. (RETA) is 458.5k compared to 459.94k over the last 3 months which indicates decrease in trading activity. Right now, Reata Pharmaceuticals, Inc. (RETA) has a 50-day moving average of $207.65 and a 200-day moving average of $148.54. These moving averages are popular technical indicators that investors use to analyze price trends of Reata Pharmaceuticals, Inc. (RETA).
Approximately 12.09% of the shares of the company are short sold from investors betting the shares might trade lower. The beta value on Reata Pharmaceuticals, Inc. (RETA) stock is 2.57, indicating its 5.72% to 4.96% more volatile than the overall global market.
Technically, RETA’s short term support levels are around $215.52, $200.15 and $184.36 on the downside. RETAs short term resistance level is $260.68 on the upside.
Based on technical analysis, RETA has short term rating of Neutral (-0.02), Intermediate rating of Neutral (0.23) and the long-term rating of Bullish (0.34) giving it an overall rating of Neutral (0.18).
RETA is trading 212.56% off its 52 week low at $70.00 and -2.76% off its 52 week high of $225.00. Performance wise, RETA stock has recently shown investors 13.08% a greater amount in a week, 7.02% a greater amount in a month and 7.03% a greater amount in the past quarter.
On the flip side, Reata Pharmaceuticals, Inc. (RETA) has shown a return of 7.02% since the beginning of the year.
Reata Pharmaceuticals, Inc. (RETA) Key Details:
Reata Pharmaceuticals, Inc. (RETA) is a mid cap company with a market cap value of $7.257B. RETA insiders hold roughly 5.36% of the shares.
On Sep-25-18 Leerink Partners Reiterated RETA as Outperform at $116 → $139. On Sep-26-19 National Securities Initiated RETA as Buy at $130 and on Nov-13-19 National Securities Downgrade RETA as Buy → Neutral.
There are currently 25.25M shares in the float and 29.30M shares outstanding. There are 12.09% shares short in RETAs float.
The industry rank for Reata Pharmaceuticals, Inc. (RETA) is 83 out of 255 ranking it at the Top 33% .
Reata Pharmaceuticals, Inc. (RETA) Key Fundamentals:
RETA last 2 years revenues have decreased from $53,589 to $32,298 showing a downtrend.
Wall Street expects Reata Pharmaceuticals, Inc. (RETA) to report an EPS next Qtr loss of -3.12 and a loss of -11.70% next year.
The growth rate on RETA this year is -86.76 compared to an industry 8.10. However, RETAs next year’s growth rate is -28.73 compared to an industry 8.10.
The book value per share (mrq) is -2.24 and cash per share (mrq) is 8.19.
RETA fundamental ratios shows an EPS growth vs. previous year -5.36 and EPS growth vs. previous quarter -2.21.
About Reata Pharmaceuticals, Inc. (RETA):
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States.